[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":404},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,45,69,97,117,143,161,183,215,243,271,297,322,342,363,385],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":4},"100633210","screening-and-management-of-adults-with-asthma-and-allergic-diseases-100633210",false,"NCT07523724","Screening and Management of Adults With Asthma and Allergic Diseases","Inclusion Criteria:\n\n* Aged ≥18 years\n* Capable of providing informed consent and completing the questionnaire independently.\n\nExclusion Criteria:\n\n* Individuals with serious chronic diseases, immune disorders, or severe psychiatric\u002Fcognitive conditions.","ALL","18 Years","60 Years",{"count":19,"type":20},9666,"ESTIMATED","INTERVENTIONAL",[23],"NA","The aim of this study is to develop and validate a digital screening tool and digital management system for asthma and allergic diseases among Chinese adults and to evaluate the effectiveness of integrated non-pharmacological interventions in improving disease control and quality of life.\n\nThe digital management cohort consists of:\n\n* At least 12 months of longitudinal monitoring of symptoms, environmental exposures, and health behaviors via a digital platform, supplemented by regular clinical assessments.\n* 3x embedded randomized controlled trials (RCTs) evaluating the clinical efficacy of non-pharmacological strategies: allergen avoidance (anti-mite bedding), physical activity (wearable-guided exercise), and dietary management (Mediterranean diet).",[26,27],"Asthma","Allergic Disease",[29,26,30,31,32],"Allergic diseases","Questionnaire development and validation","Digital health","China","NOT_YET_RECRUITING","2026-04-06",{"date":36,"type":37},"2026-04-13","ACTUAL",{"date":39,"type":20},"2026-09-01",{"date":41,"type":20},"2027-12-30",{"name":43,"class":44},"Beijing Hospital","OTHER_GOV",{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":53,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100623576","metabolic-characteristics-and-prognostic-model-of-acute-coronary-syndrome-complicated-with-obstructive-sleep-apnea-100623576","NCT07398430","Metabolic Characteristics and Prognostic Model of Acute Coronary Syndrome Complicated With Obstructive Sleep Apnea","Metabolic Characteristics Analysis and Precise Prognostic Model Establishment for Patients With Acute Coronary Syndrome Complicated With Obstructive Sleep Apnea","OSA-ACS-Met","Inclusion Criteria:\n\n* Age 18-85 years.\n* Diagnosed with ACS, including ST-segment elevation myocardial infarction, non-ST-segment elevation myocardial infarction, and unstable angina.\n* Willing to participate and sign the informed consent form.\n\nExclusion Criteria:\n\n* Cardiogenic shock or cardiac arrest.\n* Central sleep apnea or other types of sleep disordered breathing.\n* Previous or current treatment with continuous positive airway pressure.\n* Inability to complete polysomnography or invalid data.\n* Malignancy or life expectancy \\\u003C 1 year.","85 Years",{"count":55,"type":20},1200,"12 Months","OBSERVATIONAL","Obstructive sleep apnea (OSA) significantly increases the risk of cardiovascular events in patients with acute coronary syndrome (ACS), yet the underlying metabolic mechanisms remain unclear. This study aims to analyze the metabolic characteristics of ACS patients with OSA using metabolomics based on a prospective cohort. The study intends to construct an artificial intelligence-based risk stratification model to improve prognosis prediction and facilitate precision medicine for this population.",[60],"Sleep Disordered Breathing (SDB)","2026-02-04",{"date":63,"type":37},"2026-02-09",{"date":65,"type":20},"2026-02-01",{"date":67,"type":20},"2027-12-31",{"name":43,"class":44},{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100570163","electroacupuncture-treatment-for-discogenic-low-back-pain-100570163","NCT06703671","Electroacupuncture Treatment for Discogenic Low Back Pain","The Efficacy and Safety of Electroacupuncture Compared With Sham Acupuncture in Patients With Discogenic Low Back Pain: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n1. It meets the diagnostic criteria of discogenic low back pain\n2. Betweening 18 and 70 years of age (both 18 and 70) and of either sex\n3. Visual analog score (VAS) for low back pain ≥40 mm within the last 1 month\n\nExclusion Criteria:\n\n1. Patients with symptoms such as lower limb numbness, weakness and claudication as shown by lumbar disc herniation pressing the spinal nerve on imaging\n2. Lumbar tuberculosis, tumor, infection, spinal fracture, lumbar spondylolisthesis, severe osteoporosis\n3. Patients with a history of spinal and intervertebral disc surgery\n4. Patients with rheumatism, rheumatoid disease, systemic lupus erythematosus, hematopoietic system, endocrine system and psychiatric diseases\n5. Patients who have received radiofrequency, minimally invasive, ozone, small needle-knife, acupuncture, manipulation, traction, block therapy and other clinical trials within the last 1 month\n6. Patients with severe needle fainting intolerance\n7. Women who are pregnant, planning pregnancy or breastfeeding\n8. People with a history of opioid analgesics, sedatives and hypnotics and alcohol abuse\n9. Patients who plan to undergo acupuncture, massage, traction and other treatments related to this disease and other clinical research trials within 3 months of participating in the study\n10. Patients with skin damage or infection, concomitant bleeding tendency, tumor metastasis, serious heart disease, or embedded pacemaker","70 Years",{"count":78,"type":20},240,[23],"Low back pain (LBP) is a prevalent clinical condition characterized by pain localized between the lower edge of the 12th rib and the gluteal fold.The incidence of LBP has been escalating annually.An epidemiological survey encompassing 204 countries and territories globally projects a stark increase in the affected population, from an estimated 619 million in 2020 to a projected 843 million by 2050.LBP can affect individuals across all age groups, with a lifetime prevalence ranging from 60% to 80%, significantly impairing quality of life. Discogenic low back pain (DLBP), attributed to degenerative changes in the intervertebral discs, is the predominant subtype of LBP, comprising approximately 39% of all LBP cases. Disc degeneration typically initiates in early adulthood and progresses with age, potentially leading to DLBP.As the population ages, DLBP has emerged as a major contributor to disability worldwide, imposing a substantial burden on both individuals and society. Current international guidelines establish the foundation for surgical and pharmacological interventions for DLBP.However, considering the adverse effects and economic implications associated with surgical and medical treatments, there is a growing inclination towards recommending non-pharmacological therapies.These include physiotherapy, self-management, and psychotherapy, with a concurrent reduction in emphasis on pharmacological and surgical options.\n\nAcupuncture and moxibustion are integral components of traditional Chinese medicine, garnering global recognition for their role in restoring the equilibrium of yin and yang within the human body . Electroacupuncture, a modern derivation of traditional acupuncture, has been extensively applied worldwide for the management of various painful conditions, including headache, myofibromyalgia, neck pain, and cancer-related pain. Despite its broad application, a limited number of clinical efficacy and safety studies have been conducted on electroacupuncture for the treatment of discogenic low back pain (DLBP), thereby necessitating a scientific foundation for its therapeutic use .\n\nThe present study aims to investigate the clinical efficacy and safety of electroacupuncture in the treatment of DLBP using an evidence-based medical approach. By employing a multicenter, randomized, and sham-controlled study design, this investigation seeks to provide a robust evidence-based medical foundation for the use of electroacupuncture in DLBP treatment.\n\nParticipants will be randomly assigned to either the acupuncture group (experimental group) or the sham acupuncture group (control group) in a 1:1 ratio, akin to a lottery drawing. Following enrollment, participants will undergo a 4-week, 12-session intervention, followed by three follow-up visits at 4, 12, and 24 weeks post-treatment. The investigators will assess participants' low back pain, lumbar spine function, and quality of life through telephone communication or on-site questioning at these designated follow-up intervals.\n\nNeedling may result in minor bleeding, pain, or hematoma at the needle site, and rare infections or allergic reactions may occur. Adverse reactions to needling, such as dizziness or nerve damage, are exceedingly rare.\n\nParticipants in this study may confer direct medical benefits, such as remission of symptoms, or may not, with outcomes ranging from no remission to potential exacerbation of the condition . However, the knowledge gained from this study is anticipated to benefit future people with similar conditions .\n\nIn addition to this study , participations may opt for treatment with modern rehabilitation medicine modalities or medications, including shortwave therapy, intermediate frequency therapy, or oral analgesics . This study would not impose any costs beyond the participants' regular medical treatment, and the investigators will cover all study-related medical expenses (including acupuncture treatment costs, needle costs, and scale evaluation costs) . The investigators are legally committed to maintaining the confidentiality of the participants' study records.",[82],"Discogenic Low Back Pain",[84,85,86,87],"Discogenic low back pain","electroacupuncture","Sham Acupuncture","A Randomized Clinical Trial","RECRUITING","2026-02-02",{"date":61,"type":37},{"date":92,"type":37},"2025-03-08",{"date":94,"type":20},"2026-06-01",{"name":43,"class":44},1,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":103,"targetDuration":105,"studyType":57,"phases":4,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100615673","external-validation-of-ischemia-and-hemorrhage-risk-models-in-patients-with-coronary-heart-disease-100615673","NCT07295665","External Validation of Ischemia and Hemorrhage Risk Models in Patients With Coronary Heart Disease","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* Patients with clinically diagnosed various types of coronary heart disease, who are scheduled to receive long-term antithrombotic treatment;\n* Patients with acute coronary syndrome or those who have undergone coronary intervention therapy, whose condition must be stable after treatment and meet the discharge criterias;\n\nExclusion Criteria:\n\n* Combination of severe non-cardiovascular diseases: Expected lifespan does not exceed 6 months, such as patients with advanced cancer or other terminal diseases;\n* Unable to cooperate with long-term follow-up: Such as patients with severe cognitive impairment or severe mental illness;\n* Non-cardiovascular death within 24 hours after admission.",{"count":104,"type":20},5000,"1 Year","Thrombosis formation is the core mechanism for the occurrence of major adverse cardiovascular and cerebrovascular events in patients with coronary heart disease. Antithrombotic therapy is one of the most important treatment methods for secondary prevention of coronary heart disease. Antithrombotic drugs, while reducing ischemic events, often significantly increase the risk of bleeding. How to balance the risk of recurrent ischemic events and bleeding events in patients with coronary heart disease is a major challenge in the treatment of coronary heart disease. This project establishes a high-quality multicenter, prospective coronary heart disease cohort, with patients covering various clinical characteristics such as different regions, ages, and comorbidities. It verifies the ischemic risk and bleeding risk model developed in Project 1, compares the efficacy improvement of the new model with the traditional risk model, and verifies the effectiveness and stability of the model in different subgroups of the population, and assesses the generalizability of the model in real-world clinical practice, providing high-quality evidence-based basis for the formulation of individualized and precise antithrombotic strategies for coronary heart disease.",[108],"Coronary Arterial Disease (CAD)","2025-12-16",{"date":111,"type":37},"2025-12-19",{"date":113,"type":20},"2026-01-01",{"date":115,"type":20},"2029-07-31",{"name":43,"class":44},{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":123,"enrollmentInfo":124,"targetDuration":126,"studyType":57,"phases":4,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":4},"100612000","research-on-the-development-and-application-of-a-preoperative-assessment-model-for-transcatheter-mitral-valve-edge-to-edge-repair-based-on-visual-foundation-models-100612000","NCT07247890","Research on the Development and Application of a Preoperative Assessment Model for Transcatheter Mitral Valve Edge-to-Edge Repair Based on Visual Foundation Models","Inclusion Criteria:\n\n1. Age: 18-90 years\n2. Patients with moderate to severe or severe mitral regurgitation as indicated by echocardiography\n\nExclusion Criteria:\n\n1. Moderate or severe aortic stenosis or aortic regurgitation, or following aortic valve replacement\n2. Patients with congenital heart disease\n3. Poor image quality: Insufficient cross-sectional coverage or inability to perform effective mitral valve marking","90 Years",{"count":125,"type":20},800,"2 Days","Mitral regurgitation (MR) is the most prevalent valvular heart disease in China. Transcatheter edge-to-edge repair (TEER) is currently the preferred treatment for patients with severe MR who face high surgical risks. However, existing preoperative assessment methods for TEER suffer from numerous limitations, including complex measurement parameters, high technical demands, and significant subjectivity. Vision Mamba, a cutting-edge technology in the visual domain, overcomes the limitations of common computational units in convolutional neural networks and Transformers through bidirectional state space models and positional encoding, demonstrating exceptional performance in visual tasks. To date, no studies have applied Vision Mamba to ultrasound videos for constructing TEER preoperative assessment models. Our team previously established a Transformer-based evaluation model using a small, single-center cohort. This study innovatively introduces a Vision Mamba-based visual foundation model. By integrating multi-faceted, multi-modal ultrasound videos from multiple centers, we develop a one-stop preoperative TEER assessment model for MR patients \\[slice identification → video analysis → multi-modal information fusion → preoperative assessment recommendation (suitable\u002Fchallenging\u002Funsuitable)\\]. This model will optimize surgical patient identification and accurately screen patients with contraindications. Furthermore, the one-stop model is fast and objective, significantly improving clinical efficiency. It holds promise for deployment at primary care levels to optimize healthcare resource allocation.",[129],"Mitral Regurgitation (MR)",[131,132,133,134],"Mitral regurgitation (MR)","Transcatheter Mitral Valve Edge-to-Edge Repair","Vision Mamba","Visual Foundation Model","2025-11-18",{"date":137,"type":37},"2025-11-25",{"date":139,"type":20},"2025-12",{"date":141,"type":20},"2027-12",{"name":43,"class":44},{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":123,"enrollmentInfo":149,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":96},"100540242","automated-echocardiographic-detection-of-coronary-artery-disease-using-artificial-intelligence-methods-100540242","NCT06314295","Automated Echocardiographic Detection of Coronary Artery Disease Using Artificial Intelligence Methods","Inclusion Criteria:\n\n* Patients with suspected coronary artery disease\n* Patients plan to undergo coronary angiography\n\nExclusion Criteria:\n\n* Patients with aortic valve stenosis\n* Patients with aortic valve replacement surgery\n* Patients with hypertrophic cardiomyopathy\n* Patients with severe heart valve disease\n* Patients with severe arrhythmia\n* Patients with severe cardiomyopathy\n* Patients with severe congenital heart disease\n* The quality of ultrasound images is poor",{"count":150,"type":20},1500,"The incidence rate and mortality of coronary artery disease are increasing year by year. Exploring non-invasive, accurate, and widely applicable methods to screen and diagnosis is of great significance. New ultrasound techniques, such as non-invasive myocardial work, have been proven to be superior to traditional ultrasound techniques in screening and diagnosis. However, diagnostic analysis based on ultrasound video images is time-consuming and subjective. The progress of artificial intelligence technology in fully automated quantitative evaluation of video images provides the possibility for computer-aided design screening and diagnosis. At present, the application of artificial intelligence in computer-aided design is a cutting-edge issue in the field of cardiovascular disease research. The application of artificial intelligence technology in the construction of computer-aided diagnostic models based on ultrasound video images is still in its early stages.",[153],"Coronary Artery Disease",{"date":155,"type":37},"2025-11-21",{"date":157,"type":37},"2024-03-11",{"date":159,"type":20},"2026-05-11",{"name":43,"class":44},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":15,"minAge":168,"maxAge":123,"enrollmentInfo":169,"targetDuration":170,"studyType":57,"phases":4,"briefSummary":171,"conditions":172,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100604002","multi-modal-intelligent-diagnosis-system-for-multiple-ophthalmic-diseases-100604002","NCT07143851","Multi-modal Intelligent Diagnosis System for Multiple Ophthalmic Diseases","Research on Key Technologies of Intelligent Auxiliary Diagnosis for Multiple Eye Diseases Based on Multimodal Ultra-High-Speed SS-OCT\u002FOCTA","Inclusion Criteria:\n\n* Diagnosed as macular degeneration, diabetic macular edema, retinal vein obstructive macular edema, high myopia, glaucoma or other clearly diagnosed ophthalmic diseases. The SS-OCT\u002FSS-OCTA images of the patient are clear.\n\nExclusion Criteria:\n\n* The image quality is poor and difficult to analyze due to reasons such as refractive media opacity and poor coordination.","20 Years",{"count":104,"type":20},"1 Day","Aiming at the problems of low image reading efficiency, crowded medical resources and fragmented cross-modal information of ophthalmic OCT and OCTA, a multimodal large model diagnostic framework for various diseases such as retinal diseases and optic nerve damage in glaucoma is constructed to fully explore the complementary information of various images such as SS-OCT structural images, SS-OCTA vascular images and optic nerve scans. Extract cross-modal joint features to improve the accuracy of automatic diagnosis.",[173,174],"Retina Disease","Glaucoma","2025-08-19",{"date":177,"type":37},"2025-08-27",{"date":179,"type":20},"2025-08-30",{"date":181,"type":20},"2028-06-30",{"name":43,"class":44},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":15,"minAge":190,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":21,"phases":193,"briefSummary":194,"conditions":195,"keywords":197,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":210,"completionDateStruct":212,"leadSponsor":214,"locationsCount":4},"100589546","gutproh-probiotic-herbal-formula-for-self-reported-constipation-in-community-adults-100589546","NCT06955819","GUTPROH: Probiotic-Herbal Formula for Self-Reported Constipation in Community Adults","GUTPROH Trial: A Double-Blind, Randomized, Placebo-Controlled Study of Probiotic-Multiherb Formula for Self-Reported Constipation Symptoms in Community-Dwelling Adults","Inclusion Criteria:\n\n* Aged 35 years or older.\n* Self - reported good comprehensive physical health status. Have complaints of irregular bowel movement frequency and a need for improved defecation, or have a spontaneous defecation frequency of less than 3 times per week in the 2 weeks before administration, or meet two or more of the following Rome IV criteria for functional constipation (FC): ① \\>25% of defecations are difficult; ② \\>25% of defecations are dry, hard, or pellet - shaped; ③ \\>25% of defecations have a sense of incomplete evacuation; ④ \\>25% of defecations have a feeling of anorectal obstruction or blockage; ⑤ \\>25% of defecations require manual assistance; ⑥ Fewer than 3 spontaneous defecations per week.\n* Provide written informed consent voluntarily before the study and be able to fill out the subject log card and research questionnaire as required by the trial protocol.\n\nExclusion Criteria:\n\n* Frail elderly people with a score of ≥3 on the FRAIL Frailty Screening Scale.\n* Self - reported presence of loose stools.\n* Those who have undergone surgery within 30 days, had an acute gastrointestinal disease within 30 days, or have been diagnosed with severe organic diseases causing defecation difficulties (such as colon cancer, intestinal obstruction, inflammatory bowel disease, etc.).\n* Patients with severe systemic diseases in the acute phase of cardiovascular, liver, kidney, and hematopoietic systems.\n* Patients with symptoms of yin deficiency and internal heat, such as dry mouth, night sweats, restlessness of the five centers (palms, soles, and chest), hard and dry stools with bad breath, red tongue with yellow coating.\n* Those who have taken antibiotics within 30 days before the start of the trial.\n* Those who have taken probiotics, fermented products, other laxative drugs, or health supplements within 14 days before the start of the trial (i.e., during the wash - out period).\n* Those who have not signed the informed consent form. Other situations considered unsuitable for enrollment by the researchers.","35 Years",{"count":192,"type":20},300,[23],"The goal of this clinical trial is to evaluate the effects of probiotic combined with or without herbal powder on relieving constipation and improving the gut microbiota in community - dwelling people with a demand for improved bowel movements through human feeding trials, and to explore their potential mechanisms of action.\n\nThe main research questions are as follows:\n\nCan the probiotic combined with or without herbal powder significantly increase the frequency of defecation in subjects, and at the same time improve fecal characteristics and defecation conditions? Can the the probiotic combined with or without herbal powder regulate the gut microbiota? What are the biological mechanisms by which the probiotic combined with or without herbal powder improve constipation and gut microbiota function? Researchers will compare experimental group 1 (taking the compound probiotic combined with herbal powder), experimental group 2 (taking probiotics alone) with the placebo control group (taking an identical - looking blank matrix powder) to observe their effects on defecation and the gut microbiota.\n\nThe main tasks for participants include:\n\nTaking the compound probiotic combined with herbal powder (experimental group 1), probiotics alone (experimental group 2), or blank matrix powder (placebo control group) as required for 12 weeks.\n\nRecording daily defecation frequency, defecation conditions, fecal characteristics, and daily diet, and reporting any adverse reactions.\n\nLongitudinal monitoring employs serial assessments comprising: 1) physical examinations (mental status\u002Fvital signs); 2) laboratory diagnostics (hematology\u002Furinalysis\u002Ffecal routine tests, hepatic-renal-metabolic panels); 3) ECG and abdominal ultrasonography; and 4) advanced analyses (gut microbiome sequencing and serum metabolomic profiling via LC\u002FMS\u002FMS).",[196],"Functional Constipation (FC)",[198,199,200,201,202,203,204,205,206],"Probiotic","Herbal powder","Functional constipation","Gut microbiota","Randomized controlled trial","Placebo control","Community population","Efficacy evaluation","Mechanism exploration","2025-06-23",{"date":209,"type":37},"2025-06-26",{"date":211,"type":20},"2025-07-10",{"date":213,"type":20},"2025-12-31",{"name":43,"class":44},{"id":216,"slug":217,"hasResults":11,"nctId":218,"briefTitle":219,"officialTitle":220,"acronym":4,"eligibilityCriteria":221,"healthyVolunteers":11,"sex":222,"minAge":16,"maxAge":223,"enrollmentInfo":224,"targetDuration":4,"studyType":21,"phases":226,"briefSummary":227,"conditions":228,"keywords":232,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":242},"100540418","clinical-study-on-dry-needling-for-primary-dysmenorrhea-and-its-preliminary-correlation-with-acupoints-100540418","NCT06316583","Clinical Study on Dry Needling for Primary Dysmenorrhea and Its Preliminary Correlation With Acupoints","Clinical Study of Dry Needling on Myofascial Trigger Points Treatment for Primary Dysmenorrhea and Preliminary Investigation of Its Relevance to Acupoints","Inclusion Criteria:\n\n1. All participants diagnosed explicitly by a gynecologist as having primary dysmenorrhea without pelvic organic lesions.\n2. Aged between 18 and 30 years.\n3. A history of cyclical menstrual pain for more than 2 years.\n4. Pain greater than 30mm on the Visual Analog Scale (VAS, 0-100mm).\n5. Participants must sign an informed consent form and be willing to undergo acupuncture treatment and cooperate to complete the relevant procedures of this trial.\n\nExclusion Criteria:\n\n1. Those suffering from secondary dysmenorrhea or any other reproductive and urinary system diseases, such as endometriosis.\n2. A history of pregnancy, miscarriage, or planning for pregnancy. Individuals with skin infections on the abdomen and lower back.\n3. Past use of acupuncture therapy or other needling treatments.\n4. Those with a history of mental illness and severe diseases of the heart, liver, brain, kidneys, hematopoietic system, etc.\n5. Within the past 6 months, individuals referred to pain clinics, those who have used pain relievers like morphine or pethidine, or those allergic to NSAIDs. Also, those currently taking or receiving anticoagulant medications.\n6. Individuals who have had adverse reactions to acupuncture (e.g., fainting).","FEMALE","30 Years",{"count":225,"type":20},150,[23],"Primary dysmenorrhea refers to menstrual pain not caused by pelvic organic lesions, commonly seen in young women, significantly affecting patients' quality of life. Dry needling therapy targeting myofascial trigger points for primary dysmenorrhea has been preliminarily applied in clinical settings. However, related research is limited with questionable quality, hindering its widespread clinical application. Furthermore, is there a connection between myofascial trigger points in dry needling and acupuncture acupoints in terms of selection and mechanism of action? Could this be a new interpretation of acupuncture theory? These are important questions that have garnered widespread attention. This study employs a randomized patient-blinded controlled design, enrolling primary dysmenorrhea patients aged 18 to 30 years. They are randomly divided into three groups: the trigger point dry needling group, traditional acupuncture treatment group, and trigger point sham needle (placebo) group. Changes in pain levels, quality of life scores, inflammatory factor levels, and local blood flow before and after treatment among the three groups are observed. The aim is to assess the therapeutic effects of dry needling trigger points and acupuncture treatments on primary dysmenorrhea and explore their potential mechanisms of action. By comparing the differences and similarities between dry needling trigger points and acupuncture treatments in terms of acupoint selection, treatment effects, and potential mechanisms of action, this study seeks to preliminarily explore the feasibility of integrating trigger point theory into the meridian 'acupoint' theory, laying the foundation for a modern interpretation of acupuncture",[229,230,231],"Trigger Point Pain, Myofascial","Acupuncture","Primary Dysmenorrhea",[233],"trigger points, dry-needling, primary dysmenorrhea","2025-05-17",{"date":236,"type":37},"2025-05-21",{"date":238,"type":37},"2024-04-01",{"date":240,"type":20},"2026-12-31",{"name":43,"class":44},2,{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":21,"phases":253,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":269,"locationsCount":270},"100515995","phase-2-telitacicept-for-the-treatment-of-connective-tissue-disease-associated-thrombocytopenia-100515995","NCT05998759","Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","A Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated Thrombocytopenia","Inclusion Criteria:\n\n* Subjects who have been diagnosed with connective tissue disease (CTD)-associated thrombocytopenia. And CTD includes primary Sjögren syndrome (according to the 2002 American College of Rheumatology (ACR)\u002F European League against Rheumatism (EULAR) classification criteria), systemic lupus erythematosus (SLE, according to the 1997 or the 2009 ACR classification criteria), and undifferentiated connective tissue disease (according to the 1999 international classification criteria)\n* Refractory thrombocytopenia defined as:\n\nEither: Failure to maintain sustained remission after treatment by glucocorticoid and at least one immunosuppressant (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate, leflunomide and hydroxychloroquine, et al.) Or: Relapse during oral glucocorticoid tapering or after withdrawal\n\n* 50×10\\^9\u002FL\\>PLT\n* anti-nuclear antibody (ANA) positive (≥1:80, any karyotype) detected in the laboratory of each research center\n* Standard therapy should be maintained stable for at least 14 days prior to the first dose of the experimental drug or placebo. Standard therapy refers to the following treatment (monotherapy or in combination): glucocorticoid, hydroxychloroquine, and other immunosuppressants (i.e. cyclophosphamide, cyclosporine, mycophenolate mofetil, azathioprine, tacrolimus, methotrexate and leflunomide, et al.)\n* Signed informed consent form, willing or able to participate in all required study evaluations and procedures\n\nExclusion Criteria:\n\n* Vital organ lethal bleeding (including but not limited to central nervous system bleeding, digestive tract bleeding) at screening, or intracranial bleeding 6 months prior to screening\n* Antiphospholipid syndrome, thrombotic thrombocytopenia purpura, hemolytic uremic syndrome, or thrombocytopenia secondary to other causes (such as sepsis, Epstein-Barr virus infection, cytomegalovirus infection, Corona Virus Disease-19 (COVID-19) infection, drugs, etc.)\n* Hematopoietic system disorders, such as myelodysplastic syndrome, paroxysmal sleep hemoglobinuria, aplastic anemia, leukemia, lymphoma, myelofibrosis and so on\n* Severe cardiovascular system disease, including: unstable or uncontrollable disease or condition affecting the function of the heart (such as angina pectoris, congestive heart failure, uncontrolled hypertension or arrhythmia)\n* Arteriovenous thromboembolism events\n* Receiving antiplatelet or anticoagulant therapy at screening\n* Clinically significant electrocardiogram changes\n* corrected Q-T interval (QTc)\\>450ms for male, QTc\\>470ms for female\n* Severe pulmonary disease, including: unstable or uncontrollable disease or condition affecting respiratory function \\[e.g., diffuse alveolar hemorrhage, severe pulmonary hypertension, severe pulmonary interstitial disease (peripheral blood oxygen saturation \\\u003C92% at rest without oxygen, or forced vital capacity (FVC)\\\u003C50%, or carbon monoxide diffusing capacity (DLCO)\\\u003C50%)\\]\n* Severe kidney disease, including: severe lupus nephritis (urinary protein \\> 6 g\u002F24 hours or endogenous creatinine clearance \\\u003C 30 ml \u002Fmin) 8 weeks prior to randomization, active nephritis requiring current protocol disallowed drugs, severe renal insufficiency requiring hemodialysis or prednisone ≥100mg\u002F day (or equivalent) for ≥14 days\n* SLE or non-SLE related central nervous system disease (including epilepsy, psychosis, organic encephalopathy syndrome, cerebrovascular accident, encephalitis, central nervous system vasculitis) 8 weeks prior to randomization\n* Active hepatitis, a history of severe liver disease. Subjects positive for hepatitis B surface antigen (HBsAg) or antibodies to hepatitis C virus are excluded. As for subjects with antibodies to hepatitis B core antigen (HBcAb), further hepatitis B virus (HBV)-DNA should be tested. If HBV-DNA is negative, subjects could be enrolled; otherwise, subjects should be excluded\n* Abnormal laboratory results (including but not limited to: alanine aminotransferase (ALT) or aspertate aminotransferase (AST)≥3×ULN (upper limit of normal), white blood cell count \\\u003C1.5×10\\^9\u002FL)\n* Subjects with known active infections (e.g., shingles, COVID-19, HIV, active tuberculosis, etc.), and active or recurrent gastrointestinal ulcers\n* Pregnant or lactating women, and subjects with a during plan during the trial\n* Allergic reaction: history of allergic reactions to human biological products\n* Treatment with B cell-targeting agents such as Rituximab or Epratuzumab or Belimumab six months prior to randomization\n* Treatment with tumor necrosis factor (TNF) inhibitors or TNF-receptor blockers six months prior to randomization\n* Participating in clinical trial 28 days or 5 drug half-lives of the investigational agents prior to randomization\n* Received live vaccine 28 days prior to randomization\n* Treatment with unstable dosage of thrombopoietin receptor agonists such as Eltrombopag or Romiplostim 14 days prior to randomization\n* Subjects with depression or suicidal thoughts\n* Previous treatment with telitacicept\n* B cell targeting drug therapy is not tolerated or responsive\n* Investigator considers candidates not appropriating for the study","75 Years",{"count":252,"type":20},296,[254],"PHASE2","The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.",[257,258],"Connective Tissue Diseases","Thrombocytopenia",[257,258,260,261,262],"biological agents","B cell","targeted therapy","2025-05-03",{"date":265,"type":37},"2025-05-06",{"date":267,"type":37},"2023-12-02",{"date":139,"type":20},{"name":43,"class":44},23,{"id":272,"slug":273,"hasResults":11,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":278,"targetDuration":4,"studyType":21,"phases":280,"briefSummary":281,"conditions":282,"keywords":286,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":290,"lastUpdatePostDateStruct":291,"startDateStruct":293,"completionDateStruct":295,"leadSponsor":296,"locationsCount":5},"100361527","comparing-the-efficacy-and-safety-between-continuous-subcutaneous-beinaglutide-and-csii-for-newly-diagnosed-t2dm-patients-100361527","NCT03987308","Comparing the Efficacy and Safety Between Continuous Subcutaneous Beinaglutide and CSII for Newly Diagnosed T2DM Patients","Comparing the Efficacy and Safety Between Short-term Continuous Subcutaneous Beinaglutide Injection and Continuous Subcutaneous Insulin Infusion (CSII) for Treatment of Patients With Newly Diagnosed Type 2 Diabetes: a Multicenter, Randomized Open Trial Study With Parallel Controls","Inclusion Criteria:\n\n1. Age 18 to 70 years (inclusive) at enrollment, regardless of gender.\n2. Voluntary signing of the informed consent form.\n3. Newly diagnosed type 2 diabetes mellitus patients, diagnosed according to the WHO 1999 criteria, with a disease duration ≤1 year.\n4. HbA1c between 7.5% and 10.0%.\n5. BMI between 24 kg\u002Fm² and 42 kg\u002Fm².\n6. Subjects who have not taken antidiabetic medications or have used oral antidiabetic medications for less than 3 months and have discontinued for more than 1 month (calculated from the date of signing the informed consent form).\n7. Subjects with reproductive potential (including male subjects whose partners have reproductive potential) agree to use effective contraception during the study and for 1 month after study completion.\n\nExclusion Criteria:\n\n1. Patients with type 1 diabetes or other types of diabetes.\n2. History of obstructive intestinal diseases or potential complications: subjects with post-abdominal surgery or peritoneal infection-related intestinal adhesions, intestinal obstruction sequelae; subjects with intestinal motility disorders, chronic constipation; subjects with a history of Crohn's disease or ulcerative colitis.\n3. History of pancreatitis.\n4. Family history of medullary thyroid carcinoma.\n5. History of malignant tumors.\n6. ALT, AST \\>3 times the upper limit of normal, and\u002For total bilirubin \\>2 times the upper limit of normal.\n7. Moderate to severe renal insufficiency (eGFR \\\u003C60 ml\u002Fmin\u002F1.73m²).\n8. Triglycerides ≥5.0 mmol\u002FL.\n9. Multiple endocrine neoplasia type 2 (MEN 2).\n10. Participation in any pre-marketing drug study within 3 months.\n11. Use or expected use of systemic corticosteroids, immunosuppressants, or cytotoxic drugs during the study period.\n12. History of diabetic ketoacidosis or non-ketotic hyperosmolar coma within 6 months prior to screening.\n13. Blood pressure exceeding the following criteria (untreated or treated): systolic blood pressure ≥160 mmHg and\u002For diastolic blood pressure ≥100 mmHg.\n14. History of any of the following cardiovascular diseases within 3 months prior to screening: acute myocardial infarction, New York Heart Association functional class III\u002FIV heart failure or left ventricular ejection fraction ≤40%, or cerebrovascular event (stroke).\n15. Allergy to binaclotide or any component of the study drug, or allergy to insulin or any component of the insulin used in the study.\n16. Presence of other severe diseases that may interfere with the study, as judged by the investigator.\n17. Pregnant or breastfeeding women.\n18. Poor compliance, as judged by the investigator, and inability to complete the study as required.\n19. Inability to undergo continuous pump infusion: subjects allergic to subcutaneous infusion tubes or adhesive tape; subjects unwilling to have long-term subcutaneous infusion tubes or continuous pump use; subjects with psychological aversion to pump therapy; subjects or their families lack relevant knowledge and are unable to master the use after training; subjects with severe psychological disorders or mental abnormalities; subjects who are unable to care for themselves and have no caregivers.\n20. Any other factors deemed unsuitable for participation in the study by the investigator.",{"count":279,"type":20},115,[23],"The efficacy, safety and post-treatment disease control will be compared between groups of continuous subcutaneous Beinaglutide infusion and continuous subcutaneous insulin infusion (CSII) in adult patients with newly diagnosed type 2 diabetes.",[283,284,285],"Type 2 Diabetic Patients","T2DM (Type 2 Diabetes Mellitus)","T2DM",[285,287,288,289],"beinaglutide","CSII","subcutaneous pump","2025-04-30",{"date":292,"type":37},"2025-05-02",{"date":294,"type":37},"2019-07-02",{"date":139,"type":20},{"name":43,"class":44},{"id":298,"slug":299,"hasResults":11,"nctId":300,"briefTitle":301,"officialTitle":301,"acronym":302,"eligibilityCriteria":303,"healthyVolunteers":11,"sex":15,"minAge":250,"maxAge":4,"enrollmentInfo":304,"targetDuration":306,"studyType":57,"phases":4,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":319,"leadSponsor":321,"locationsCount":96},"100583764","seniors-integrated-longitudinal-cardiovascular-evaluation-of-coronary-heart-disease-a-multicenter-prospective-registry-in-china-silver-china-100583764","NCT06880575","Seniors Integrated Longitudinal cardioVascular Evaluation of Coronary Heart Disease: a Multicenter, Prospective Registry in China (SILVER-China)","SILVER-China","Inclusion Criteria:\n\n① Age requirements: Participants are ≥ 75 years old;\n\n* This time he was admitted to the hospital due to angina pectoris and other coronary heart disease-related symptoms\n\n  ③ Conform to the diagnosis of coronary heart disease: meet any one of the following conditions:\n  1. This admission was performed for coronary angiography, coronary artery CTA confirmed coronary heart disease;\n  2. Previous clear coronary angiography, coronary artery Coronary heart disease diagnosed by imaging evidence such as CTA evidence;\n  3. The attending physician according to the patient's symptoms, medical history, myocardial injury markers, electrocardiogram, echo cardiography, myocardial radionuclide imaging, etc. diagnosed coronary heart disease.\n\n     ④ Informed consent: Participants must be able to understand the content of the study, voluntarily participate in the study, and sign the informed consent form.\n\n     Exclusion Criteria:\n     * Combined with severe non-cardiovascular disease: life expectancy does not exceed 6 months, such as advanced cancer or other end-stage disease;\n* Unable to cooperate with long-term follow-up: such as patients with severe cognitive impairment or severe mental illness; ③ Non-cardiogenic death within 24 hours after admission.",{"count":305,"type":20},10139,"5 Years","This study aims to establish a nationwide cohort and biobank of elderly patients with coronary heart disease (CHD) and to develop risk prediction models and clinical treatment optimization plans based on this data. The specific research content is as follows:\n\nThe Study plan to continuously enroll hospitalized elderly CHD patients across 50 centers nationwide. Using networked electronic data collection technology, standardized methods and protocols will be used to gather demographic information (such as age, gender, education level, income, etc.), clinical information (medical history, past treatment records, current treatment plans, surgical records, medication use, etc.), lifestyle information (dietary habits, exercise frequency, smoking, drinking, etc.), biological information (such as inflammatory markers, etc.), and physical examination data (such as blood pressure, ECG, sleep monitoring, imaging examinations, etc.). These patients will be followed up long-term (1 month, 6 months, 1 year, and annually thereafter for up to 5 years) to establish a database that meets international standards. Centers meeting the criteria will also retain biological samples, creating a multicenter biobank for elderly CHD patients.\n\nSecond, based on the established clinical cohort, a risk prediction model for elderly CHD patients will be developed, including mortality risk, ischemic risk, bleeding risk, etc. Additionally, optimized clinical diagnostic and treatment plans will be formulated to improve the treatment outcomes and quality of life for elderly CHD patients. This research is expected to provide scientific evidence and technical support for the prevention, diagnosis, and treatment of CHD in elderly patients.",[108,309],"ELDERLY PEOPLE",[311,312,313],"Coronary Heart Disease","Chinese Elderly","Cohort Study","2025-03-14",{"date":316,"type":37},"2025-03-17",{"date":318,"type":37},"2024-11-06",{"date":320,"type":20},"2027-06-30",{"name":43,"class":44},{"id":323,"slug":324,"hasResults":11,"nctId":325,"briefTitle":326,"officialTitle":327,"acronym":4,"eligibilityCriteria":328,"healthyVolunteers":11,"sex":15,"minAge":329,"maxAge":4,"enrollmentInfo":330,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":341,"locationsCount":4},"100560896","prediction-model-of-treatment-efficacy-for-age-related-macular-degeneration-based-on-multi-source-imaging-modalities-100560896","NCT06583109","Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities","Establishment and Application of Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities","Inclusion Criteria:\n\n* Patients diagnosed with nAMD by ophthalmic examinations including OCT, OCTA, FFA and ICGA;\n* Complete clinical data and imaging data of patients were available at baseline, 3 months and 1 year after anti-VEGF treatment.\n\nExclusion Criteria:\n\n* Medical records showed other diseases affecting visual function or fundus imaging, such as macular edema, glaucoma, ocular trauma, etc;\n* Medical records showed that two or more macular lesions coexist in the affected eye;\n* Medical records showed that patients received other treatments within 1 year of anti-VEGF therapy, such as intraocular laser therapy or ocular surgery;\n* Medical records showed that there were ocular media opacity, dense macular hemorrhage, or severe macular atrophy, resulting in the inability to accurately measure the required parameters;\n* Medical records showed the use of drugs known to cause retinal toxicity, or a history of radiation exposure.","50 Years",{"count":331,"type":20},2600,"Age-related macular degeneration (AMD) is one of the main causes of blindness in the elderly population. Intraocular injection of anti-VEGF drugs for neovascular AMD (nAMD) is the main treatment method at present. However, patients have different responses to anti-VEGF therapy, and some patients do not respond well to short - and long-term treatment.\n\nIn this study, a retrospective study was adopted to collate and analyze the clinical data and imaging data of nAMD in the past, and to extract the imaging features from the multimodal modalities before and after treatment for deep learning, and to evaluate and quantify the clinical features, and to construct two multi-source feature models for predicting the short-term and long-term prognosis of nAMD patients. By verifying the accuracy of the model to predict the curative effect, the classification efficiency of the above characteristic models was compared, and the optimal model was selected. Its clinical application value was evaluated by calibration curve and decision curve. In addition, patients with poor treatment response in the study cohort were retrospectively analyzed, and the efficacy and safety of the combination of other treatment options in the actual clinic were analyzed. The purpose of this study is to provide scientific basis for early prediction, dynamic monitoring and optimization of overall treatment strategies for nAMD.",[334],"Age-related Macular Degeneration (ARMD)","2024-09-01",{"date":337,"type":37},"2024-09-03",{"date":339,"type":20},"2024-10-01",{"date":94,"type":20},{"name":43,"class":44},{"id":343,"slug":344,"hasResults":11,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":76,"enrollmentInfo":349,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":360,"leadSponsor":362,"locationsCount":4},"100552088","combination-of-micropulse-laser-with-or-without-photodynamic-therapy-for-chronic-central-serous-chorioretinopathy-100552088","NCT06468540","Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy","Comparative Study on the Efficacy of the Combination of Micropulse Laser With or Without Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinal Disease","Inclusion Criteria:\n\n* Age \\>18 years old.\n* The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. The diagnostic criteria for chronic CSC were as follows: FFA examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. Fundus examination showed superficial detachment of retinal neuroepithelium in macula.\n* Patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment.\n* Patients had follow-up data before and after treatment for 1 month and at least 6 months.\n\nExclusion Criteria:\n\n* Patients with other fundus diseases or refractive interstitial opacity.\n* During treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received.\n* Various reasons led to incomplete patient data.",{"count":350,"type":20},60,"In this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. The visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. We will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.",[353,354,355],"Central Serous Chorioretinopathy","Micropulse Laser","Photodynamic Therapy","2024-06-15",{"date":358,"type":37},"2024-06-21",{"date":356,"type":20},{"date":361,"type":20},"2025-12-15",{"name":43,"class":44},{"id":364,"slug":365,"hasResults":11,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":21,"phases":371,"briefSummary":372,"conditions":373,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":377,"lastUpdatePostDateStruct":378,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":96},"100540764","phase-2-ice-study-combination-of-irinotecan-plus-cetuximab-and-envafolimab-as-a-rechallenge-regimen-in-mcrc-100540764","NCT06321081","ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","ICE Study: a Clinical Study of the Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","Inclusion Criteria:\n\n* Signed written informed consent before any trial-related procedure is undertaken that is not part of the standard patient management.\n\nMale or female subjects aged ≥ 18 years. Histologically proven diagnosis of colorectal adenocarcinoma. Diagnosis of metastatic disease. RAS (NRAS and KRAS exon 2,3 and 4) and BRAF wild-type in liquid biopsy at screening (according to NGS) Efficacy of any front-line therapies containing cetuximab or irinotecan with a major response achieved (i.e. complete or partial response according to RECIST criteria v1.1)..\n\nMore than 2 months since the last dose of cetuximab administered in first line treatment before randomization.\n\nMeasurable disease according to RECIST criteria v1.1. ECOG PS of 0 to 1 at trial entry. Estimated life expectancy of more than 12 weeks. Adequate hematological function defined by white blood cell (WBC) count ≥ 2.5 × 109\u002FL with absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL, lymphocyte count ≥ 0.5 × 109\u002FL, platelet count ≥ 100 × 109\u002FL, and hemoglobin ≥ 9 g\u002FdL (may have been transfused).\n\nAdequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range and AST and alanine aminotransferase (ALT) levels ≤ 2.5 × ULN for all subjects or AST and ALT levels ≤ 5 x ULN (for subjects with documented metastatic disease to the liver).\n\nAdequate renal function defined by an estimated creatinine clearance \\> 30 mL\u002Fmin according to the Cockcroft-Gault formula (or local institutional standard method).\n\nEffective contraception for both male and female subjects throughout the study and for at least 2 months after last study treatment administration if the risk of conception exists (Note: The effects of the trial drug on the developing human fetus are unknown; thus, women of childbearing potential and men must agree to use effective contraception, defined as 2 barrier methods, or 1 barrier method with a spermicide, an intrauterine device, or use of oral female contraceptive. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately).\n\nExclusion Criteria:\n\n* Any contraindication to cetuximab and\u002For envafolimab. Past or current history of malignancies other than colorectal carcinoma, except for curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix.\n\nPregnancy. Breastfeeding. Participation in a clinical study or experimental drug treatment within 30 days before enrollment.\n\nSubjects receiving immunosuppressive agents (such as steroids) for any reason, should be tapered off these drugs before initiation of the trial treatment, with the exception of:\n\nSubjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement dose, equivalent to ≤ 10 mg prednisone daily Intranasal, inhaled, topical steroids, Local steroid injection (e.g., intra-articular injection) Systemic corticosteroids at physiologic doses ≤ 10 mg\u002Fday of prednisone or equivalent Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) No ongoing neurological symptoms related to the brain localization of the disease (sequelae that are a consequence of the treatment of the brain metastases are acceptable) Prior organ transplantation, including allogeneic stemcell transplantation\n\nSignificant acute or chronic infections including, among others:\n\nKnown history of positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome\n\nActive autoimmune disease that might deteriorate when receiving an immunostimulatory agent:\n\nSubjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.\n\nSubjects requiring hormone replacement with corticosteroids are eligible if steroids are administered only for the purpose of hormonal replacement and at doses ≤ 10 mg or equivalent prednisone per day.\n\nAdministration of steroids through a route known to result in a minimal systemic exposure (topical, intranasal, intro-ocular, or inhalation) are acceptable.\n\nActive infection requiring systemic therapy. Previous or ongoing administration of systemic steroids for the management of an acute allergic phenomenon is acceptable as long as it is anticipated that the administration of steroids will be completed in 14 days, or that the daily dose after 14 days will be ≤ 10 mg per day of equivalent prednisone.\n\nKnown severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE v 5 Grade ≥ 3), any history of anaphylaxis, or uncontrolled asthma (that is, 3 or more features of partially controlled asthma).\n\nHistory of hypersensitivity to Polysorbate 80 that led to unacceptable toxicity requiring treatment cessation.\n\nPersisting toxicity related to prior therapy of Grade \\> 1 NCI- CTCAE v 5.0. Known alcohol or drug abuse. Clinically significant (that is active) cardiovascular disease: cerebral vascular accident\u002Fstroke (\\\u003C6 months prior to enrollment), myocardial infarction (\\\u003C6 months prior to enrollment), unstable angina, congestive heart failure (New York Heart Association Classification Class ≥ II), or serious uncontrolled cardiac arrhythmia requiring medication.\n\nHistory of keratitis, ulcerative keratitis or severe dry eye. Since contact lent use is also a risk factor for keratitis and ulceration, it is not recommended.\n\nOther severe acute or chronic medical conditions including immune colitis, inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.\n\nLegal incapacity or limited legal capacity.",{"count":350,"type":20},[254],"This is a non-profit phase II, open, clinical study of the combination of irinotecan plus cetuximab and envafolimab as a rechallenge regimen, in pre-treated RAS\u002FBRAF wild type metastatic colorectal cancer patients (according to liquid biopsy at baseline). Patients have been treated in front lines with irinotecan and cetuximab and had a clinical benefit (complete or partial response) from both of them, no matter whether they had treated by any PD-1 inhibitor before.",[374,375,376],"RAS Mutation","Metastatic Colorectal Cancer","MSS","2024-03-14",{"date":379,"type":37},"2024-03-20",{"date":381,"type":37},"2024-03-01",{"date":383,"type":20},"2026-08-14",{"name":43,"class":44},{"id":386,"slug":387,"hasResults":11,"nctId":388,"briefTitle":389,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":250,"enrollmentInfo":391,"targetDuration":4,"studyType":21,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":88,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":403,"locationsCount":96},"100496036","prevention-of-postoperative-recurrence-of-hepatocellular-carcinoma-by-blocking-rak-cells-with-anti-tim-3-100496036","NCT05738980","Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3","Inclusion Criteria:\n\n* 3\\) Patients diagnosed with HCC by histological examination; 4) According to China Liver Cancer Staging (CNLC) -- Guidelines for the Diagnosis and Treatment of primary liver Cancer of the National Health Commission of the People's Republic of China (2022 edition), patients with stage Ia and stage Ib ⅱA; 5) Undergoing radical resection of HCC; 6) For patients with hepatocellular carcinoma diagnosed by pathology after radical resection, the clinical and pathological characteristics meet one of the following conditions: A. tumor ≥5cm; B. Pathology suggested MVI (microvascular invasion); C. Pathology suggested satellite foci or sub-foci; D. Multiple tumors (number of tumors ≥2); E. AFP \\& GT; 20 mu g\u002FL; F. Accompanied by hepatic capsule invasion; 7) ECOG score 0 or 1; Child-pugh liver function score A\u002FB (≤7); 8) Neutrophil count ≥1.5×109\u002FL, lymphocyte count ≥1.1×109\u002FL, platelet count ≥80×109\u002FL; Cardiac echocardiography showed that cardiac ejection fraction ≥50%, and 12-lead ECG showed no obvious abnormalities. Oxygen saturation ≥90%; Creatinine clearance rate CG formula ≥50 mL\u002Fmin; ALT and AST 2.5 x ULN or less; Serum total bilirubin ≤1.5×ULN; 9) The estimated survival time is more than 6 months; 10) Fertile men or women with the possibility of becoming pregnant agree to use effective contraceptive methods (e.g., oral contraceptives, intrauterine devices, controlled sexual desire or barrier contraception combined with spermicide) during the trial and to continue contraception for 3 months after completion of treatment.\n\nExclusion Criteria:\n\n* 1\\) Pregnant or lactating women; 2) Previous systemic treatment: cytotoxic chemotherapy drugs within 3 months, targeted drugs within 2 months, interferon and\u002For interleukin-2 within 3 months, and leukocyte raising drugs within 2 weeks; Have been treated with drugs that target immune regulatory points; 3) Have used immunosuppressive agents (e.g., azathioprine, 6-mercaptopurine, cyclosporine, tisirolimus, everolimus, rapamycin, etc.); Long-term use of corticosteroids; 4) History of thromboembolism within the last 3 months or high risk of pulmonary embolism; 5) Previous use of DC-CIK or CIK cells, autologous RAK\u002FLAK cells or other adoptive immunotherapy; 6) A history of other malignant diseases in the last 5 years (except cured skin cancer and carcinoma in situ of the cervix); 7) Uncontrolled epilepsy, central nervous system diseases, cerebrovascular accidents, or accompanied by other uncontrolled diseases; A history of mental disorders; 8) Clinically severe heart disease (NYHA) grade II or more congestive heart failure or severe arrhythmias requiring medical intervention; 9) Interstitial lung disease ≥2 degrees; 10) Accompanied by fever or infection; 11) Autoimmune diseases, including uncontrolled hypothyroidism and hyperthyroidism; 12) HIV\u002FAIDS or syphilis antibody positive; 13) Allergic to any interferon and interleukin-2 preparations; 14) Participating in other trials within 4 weeks before enrollment; 15) Poor compliance or conditions deemed inappropriate for study inclusion by the investigator.",{"count":392,"type":20},88,[23],"To compare the safety and efficacy of unmodified RAK cells and anti-TIM-3 blocked autologous RAK cells in preventing postoperative recurrence of HCC by postoperative TACE therapy combined with immune cell therapy.",[396],"Hepatocellular Carcinoma","2023-02-13",{"date":399,"type":37},"2023-02-22",{"date":401,"type":37},"2023-02-01",{"date":240,"type":20},{"name":43,"class":44},""]